Opus Genetics to Present OPGx-BEST1 Cohort 1 Clinical Data in Investor Webcast and at Upcoming Leading Ophthalmology Conferences
Opus Genetics will present topline data from Cohort 1 of its Phase 1/2 study of the OPGx-BEST1 gene therapy during an investor conference call and webcast on Wednesday, September 9, 2026, at 8:00 a.m. ET. The full clinical dataset and additional visual-function analyses will also be presented at upcoming medical meetings, including the Euretina Innovation Spotlight (September 30), Euretina 2026 (October 4), Retina in Rio (October 14), and FLORetina, with presentations from Mark Pennesi, CEO George Magrath, and other retinal specialists.
Key figures
- Drug Name
- OPGx-BEST1
- Phase Of Trial
- Phase 1/2 (Phase 1b/2a)
- Webcast datetime
- September 9, 2026, 8:00 a.m. ET
- Pipeline programs
- 7
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.